
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Intrinsic Value
The intrinsic value of one
ZNTL
stock under the Base Case scenario is
1.06
USD.
Compared to the current market price of 1.36 USD,
Zentalis Pharmaceuticals Inc
is
Overvalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Zentalis Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Zentalis Pharmaceuticals Inc
Balance Sheet Decomposition
Zentalis Pharmaceuticals Inc
Current Assets | 386.1m |
Cash & Short-Term Investments | 371.1m |
Receivables | 7.9m |
Other Current Assets | 7m |
Non-Current Assets | 44.3m |
PP&E | 37.2m |
Other Non-Current Assets | 7m |
Free Cash Flow Analysis
Zentalis Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Zentalis Pharmaceuticals Inc
Revenue
|
67.4m
USD
|
Operating Expenses
|
-254.9m
USD
|
Operating Income
|
-187.5m
USD
|
Other Expenses
|
21.6m
USD
|
Net Income
|
-165.8m
USD
|
ZNTL Profitability Score
Profitability Due Diligence
Zentalis Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Score
Zentalis Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
ZNTL Solvency Score
Solvency Due Diligence
Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ZNTL
is 6.4 USD
with a low forecast of 2.22 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for ZNTL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ZNTL
stock under the Base Case scenario is
1.06
USD.
Compared to the current market price of 1.36 USD,
Zentalis Pharmaceuticals Inc
is
Overvalued by 22%.